- Dúvidas?
- 61 2191-5070
- contato@vbrf.com.br
Since 1974, we have built a history of innovation, quality, and commitment to providing access to advanced technologies, establishing our position as a national reference in radiopharmaceuticals and imaging diagnostics.
The Villas Boas Group began its activities in 1974 with the founding of Clínica Villas Boas, dedicated to the fields of Radiology and Nuclear Medicine. Since then, it has established itself as a national reference in diagnostic imaging, marking its history with pioneering efforts and the introduction of advanced technologies in the country.
Continuing this movement of innovation, Villas Boas Radiofármacos Brasil was inaugurated in 2006 — the first private industrial radiopharmacy in Brazil to produce radiopharmaceuticals using a cyclotron. A cyclotron is a charged‑particle accelerator that, by bombarding a specific target, triggers nuclear reactions capable of generating the radioactive material used in radiopharmaceutical synthesis.
This initiative played a key role in expanding access to short‑half‑life radiopharmaceuticals to the North, Northeast, and Central‑West regions of Brazil, directly contributing to the strengthening of Brazilian Nuclear Medicine.
Our commitment to advancing the sector was strengthened in 2017 with the establishment of our second industrial facility, located in the municipality of Eusébio, in the state of Ceará. Today, our manufacturing units produce and distribute FDG and 18F‑PSMA radiopharmaceuticals nationwide, following rigorous quality and regulatory compliance standards.
Our operations rely on teams composed of pharmacists, physicists, engineers, physicians, and technicians—many of whom have been with us since the company’s founding. The experience accumulated over nearly two decades of industrial operation is continuously shared with new team members, supporting a solid technical culture focused on excellence. This combination of tradition, expertise, and operational capability underpins our role in advancing Nuclear Medicine in Brazil.”
Quality assurance guides our entire production structure, from process development to the distribution of radiopharmaceuticals.
Production structure grounded in current legislation and in Good Manufacturing Practices (GMP), following the sector’s rigorous technical standards.
Full focus on standardization and traceability. Our procedures are continuously reviewed to ensure safety and ongoing improvement.
Strict controls and internal audits ensure batch consistency, guaranteeing reliable and safe products for clinical use.
Compliance with Good Manufacturing Practices is verified through certifications issued by the Brazilian Health Regulatory Agency (ANVISA).
These certifications reflect the strength of our quality management system, the maturity of our industrial processes, and our adherence to the technical requirements applicable to radiopharmaceutical production.
Ongoing maintenance and continuous improvement programs ensure that our manufacturing units remain aligned with regulatory standards and the growing needs of Nuclear Medicine.
